Related Experiment Video

Updated: Jun 1, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
14:04

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria

Published on: May 8, 2013

Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

Kathryn A Culos1, Joan P Cannon, Shellee A Grim

  • 1Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL 60612, USA. kclenn2@uic.edu

American Journal of Therapeutics
|June 7, 2011
PubMed

Insights

Methicillin-resistant Staphylococcus aureus (MRSA) infections pose significant risks. While vancomycin is standard, alternative treatments are emerging due to reduced susceptibility, requiring careful selection based on efficacy and safety.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Resistant gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA), are associated with increased morbidity and mortality.
  • MRSA infections, historically nosocomial, are increasingly prevalent in community settings.
  • Reduced vancomycin susceptibility in Staphylococcus aureus necessitates alternative treatment strategies.

Purpose of the Study:

  • To review currently available and investigational agents for treating MRSA infections.
  • To evaluate the efficacy and safety profiles of alternative MRSA treatment options.
  • To provide guidance on selecting appropriate agents when vancomycin use is limited.

Main Methods:

  • Literature review of clinical studies and pharmacological data on MRSA agents.
  • Analysis of efficacy, safety, and tolerability of established and novel MRSA treatments.
  • Comparison of vancomycin with alternative agents, including linezolid, quinupristin/dalfopristin, daptomycin, tigecycline, telavancin, and ceftaroline.

Main Results:

  • Linezolid and quinupristin/dalfopristin show efficacy but have potential toxicities.
  • Daptomycin, tigecycline, telavancin, and ceftaroline are well-tolerated but lack superior clinical data over vancomycin.
  • Several new agents in development exhibit MRSA activity.

Conclusions:

  • Vancomycin remains the gold standard for MRSA infections.
  • Selection of alternative agents requires consideration of patient-specific factors, cost, and clinical evidence.
  • Ongoing research is crucial for developing new effective MRSA therapies.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...